Bridgebio Pharma Inc (BBIO) - News Archive

In a recent press release, BridgeBio Pharma, a leading biopharmaceutical company focusing on genetic diseases and cancers, announced the approval of equity grants to 18 new employees. This move signifies the company s c...

Promising Outcomes from BridgeBio Pharma’s Clinical Trials: Effective Treatments for Achondroplasia and Transthyretin Amyloid CardiomyopathyBridgeBio Pharma is making significant strides in addressing rare genetic condi...

In a significant advancement for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), recent data presented at the International Society of Amyloidosis (ISA) conference showcases the promising efficacy of Ac...

Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare and life-threatening disease characterized by the accumulation of amyloid fibrils in the heart, has seen limited therapeutic options until recently. However, a grou...

In a recent press release, BridgeBio Pharma, a prominent biopharmaceutical company specializing in genetic diseases and cancers, announced the approval of equity grants for 24 new employees. These grants, in the form of...

BridgeBio Pharma recently presented additional data and analyses from its Phase 3 ATTRibute-CM study at the ESC-HF conference, shedding light on the remarkable potential of Acoramidis in treating Transthyretin Amyloid C...

BridgeBio Accelerates Oncology Pipeline with $200M FinancingBridgeBio Pharma, a leading biopharmaceutical company focused on genetic diseases and cancers, has announced the completion of a $200M private financing for it...

Facts:On April 5, 2024, the compensation committee of BridgeBio s board of directors approved equity grants to 19 new employees in restricted stock units for a total of 93,088 shares of the company s common stock. The v...

:Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterized by the deposition of misfolded transthyretin protein in cardiac tissue, leading to heart failure. Acoramidis, a novel inve...

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - A Strategic Move to Boost Genetic Disease and Cancer Research PALO ALTO, Calif., March 5, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading c...

In a groundbreaking partnership, BridgeBio Pharma and Bayer have recently announced a licensing agreement that will see Acoramidis, a potentially revolutionary therapy for transthyretin amyloid cardiomyopathy (ATTR-CM),...

In a groundbreaking partnership, BridgeBio Pharma and Kyowa Kirin have joined forces to develop and commercialize infigratinib for the treatment of skeletal dysplasias in Japan. With an upfront payment of $100 million,...

As the biopharmaceutical industry continues to evolve, BridgeBio Pharma, Inc. stands out as a leader in genetic diseases and cancers. With recent announcements of inducement grants under Nasdaq Listing Rule 5635(c)(4),...

In a significant development, BridgeBio Pharma recently announced the acceptance of the New Drug Application (NDA) for Acoramidis by the U.S. Food and Drug Administration (FDA). Acoramidis is a potential breakthrough tr...

In a groundbreaking development in the field of rare diseases, BridgeBio Pharma recently announced positive results from a single-arm Phase 3 study of Acoramidis in Japanese patients suffering from Transthyretin Amyloid...

BridgeBio Pharma Secures Funding and Grants Inducement Stock Units to Expand WorkforceBridgeBio Pharma, a leading biopharmaceutical company, recently announced a significant development in its efforts to advance the tre...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare and life-threatening disease characterized by the accumulation of abnormal transthyretin protein in the heart tissue. BridgeBio Pharma has recently published thei...

BridgeBio Pharma Grants Restricted Stock Units to New Employees: Impact on Company SharesPALO ALTO, Calif., Jan. 10, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company specializing in gene...

BridgeBio Pharma, a renowned biopharmaceutical company, made an exciting announcement today regarding the granting of inducement stock units to nineteen new employees. This move reflects the company s commitment to expa...

BridgeBio Pharma, an esteemed biopharmaceutical company dedicated to addressing genetic diseases and cancer, has recently disclosed its inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants mark a signifi...